A case of pityriasis rubra pilaris secondary to ponatinib
Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X241311341 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841554797343277056 |
|---|---|
| author | Ariana Nateghi Florence Lagacé-Thomassin Julie Desrochers |
| author_facet | Ariana Nateghi Florence Lagacé-Thomassin Julie Desrochers |
| author_sort | Ariana Nateghi |
| collection | DOAJ |
| description | Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose reduction and recurred more mildly at a lower dose. Symptomatic relief was achieved with topical tretinoin, triamcinolone, and emollients. This case underscores the importance of managing dose-dependent skin reactions while maintaining cancer therapy. |
| format | Article |
| id | doaj-art-a4a37f17ce8b4d408f72855685d8e7f9 |
| institution | Kabale University |
| issn | 2050-313X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj-art-a4a37f17ce8b4d408f72855685d8e7f92025-01-08T10:03:39ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-01-011310.1177/2050313X241311341A case of pityriasis rubra pilaris secondary to ponatinibAriana Nateghi0Florence Lagacé-Thomassin1Julie Desrochers2Department of Dermatology, Sherbrooke University, Sherbrooke, QC, CanadaDepartement of Dermatology, Laval University, Quebec, QC, CanadaDepartement of Dermatology, Charles-Le Moyne Hospital, Longueuil, QC, CanadaPonatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose reduction and recurred more mildly at a lower dose. Symptomatic relief was achieved with topical tretinoin, triamcinolone, and emollients. This case underscores the importance of managing dose-dependent skin reactions while maintaining cancer therapy.https://doi.org/10.1177/2050313X241311341 |
| spellingShingle | Ariana Nateghi Florence Lagacé-Thomassin Julie Desrochers A case of pityriasis rubra pilaris secondary to ponatinib SAGE Open Medical Case Reports |
| title | A case of pityriasis rubra pilaris secondary to ponatinib |
| title_full | A case of pityriasis rubra pilaris secondary to ponatinib |
| title_fullStr | A case of pityriasis rubra pilaris secondary to ponatinib |
| title_full_unstemmed | A case of pityriasis rubra pilaris secondary to ponatinib |
| title_short | A case of pityriasis rubra pilaris secondary to ponatinib |
| title_sort | case of pityriasis rubra pilaris secondary to ponatinib |
| url | https://doi.org/10.1177/2050313X241311341 |
| work_keys_str_mv | AT ariananateghi acaseofpityriasisrubrapilarissecondarytoponatinib AT florencelagacethomassin acaseofpityriasisrubrapilarissecondarytoponatinib AT juliedesrochers acaseofpityriasisrubrapilarissecondarytoponatinib AT ariananateghi caseofpityriasisrubrapilarissecondarytoponatinib AT florencelagacethomassin caseofpityriasisrubrapilarissecondarytoponatinib AT juliedesrochers caseofpityriasisrubrapilarissecondarytoponatinib |